Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with gene-therapy data can take hours. Ultragenyx Pharmaceutical’s SEC reports dive deep into pivotal-trial outcomes, Orphan Drug milestones, and royalty economics that move RARE’s share price. If you’ve ever scrolled through a 300-page 10-K looking for one clinical-stage update, you know the struggle.
Stock Titan solves that problem. Our AI models read every Ultragenyx quarterly earnings report 10-Q filing, flagging changes in cash runway and R&D spend. The same engine converts a dense 10-K into plain-language highlights, so understanding Ultragenyx SEC documents with AI feels effortless. Real-time alerts surface Ultragenyx Form 4 insider transactions—letting you see when executives adjust positions before key data readouts—while 8-K material events explained by the platform keep you ahead of trial announcements.
Need specifics? Explore:
- Ultragenyx insider trading Form 4 transactions and executive stock transactions Form 4 in real time.
- Ultragenyx annual report 10-K simplified with pipeline milestones, manufacturing risk factors, and revenue segmentation.
- Ultragenyx earnings report filing analysis that tracks quarter-over-quarter burn rate.
- Ultragenyx proxy statement executive compensation benchmarks against peer biotechs.
- Ultragenyx 8-K material events explained—whether it’s FDA feedback or partnership updates.
Every document arrives seconds after EDGAR posts, and AI-powered summaries convert jargon into actionable context. Stop combing through PDFs; start focusing on clinical catalysts, insider sentiment, and the bottom line—all from one streamlined dashboard.
Theodore Alan Huizenga, SVP and Chief Accounting Officer and director of Ultragenyx Pharmaceutical Inc. (RARE), reported a sale of 64 shares of common stock on 09/18/2025 at a price of $29.17 per share. The filing states the shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 50,242 shares. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Theodore A. Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported a sale of company common stock on 09/05/2025. The Form 4 shows a sale (Code S) of 84 shares at $31.39 per share. After the reported transaction the reporting person beneficially owned 50,306 shares directly. The filing explains the sale represents shares sold to pay required tax withholdings upon vesting of restricted stock units, and also notes the reporting person acquired 266 shares under the company’s Employee Stock Purchase Plan on April 30, 2025. Previously reported RSU-related shares subject to vesting are included in the total.
Ultragenyx (Nasdaq: RARE) filed an 8-K disclosing receipt of FDA Breakthrough Therapy Designation for GTX-102 (apazunersen) to treat Angelman syndrome.
The decision is supported by positive Phase 1/2 data in 74 children (ages 4-17) showing rapid, sustained and continuing developmental gains over up to three years.
Breakthrough status grants intensive FDA guidance, rolling review and potential priority review, which could materially shorten development timelines and lower regulatory risk.
The filing includes customary forward-looking statements covering clinical, regulatory and manufacturing uncertainties but announces no new financial terms.
FAQ
What is the current stock price of Ultragenyx Pharm (RARE)?
What is the market cap of Ultragenyx Pharm (RARE)?
